Explanipedia

Phase II trial of nivolumab and metformin in patients with treatment-refractory microsatellite stable metastatic colorectal cancer Open

Mehmet Akce, Batoul Farran, Jeffrey M. Switchenko, Manali Rupji, Sandra Kang , et al. · 2023

Background Preclinical studies showed metformin reduces exhaustion of tumor-infiltrating lymphocytes and potentiates programmed cell death protein-1 (PD-1) blockade. We hypothesized that metformin with nivolumab would elicit potent antitum…

FOLFIRINOX or Gemcitabine-based Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: A Multi-institutional, Patient-Level, Meta-analysis and Systematic Review Open

Dilmurodjon Eshmuminov, Botirjon Aminjonov, Russell F. Palm, Giuseppe Malleo, Ryan K. Schmocker , et al. · 2023

Impact of metformin on clinical outcomes in advanced hepatocellular carcinoma treated with immune checkpoint inhibitors Open

Sandra Kang, Lana Khalil, Ashley A. McCook‐Veal, Yuan Liu, John Galvin , et al. · 2023

Background and Aims Non‐alcoholic steatohepatitis (NASH) is a common cause of hepatocellular carcinoma (HCC) worldwide. Emerging data suggests NASH‐induced HCC could be associated with less response to immune checkpoint inhibitor (ICI)‐bas…

Survival and Prognostic Factors in Patients With Pancreatic Colloid Carcinoma Compared With Pancreatic Ductal Adenocarcinoma Open

Lana Khalil, Zhonglu Huang, Katerina Zakka, Renjian Jiang, McKenna J. Penley , et al. · 2023

Objectives Colloid carcinoma (CC) is a rare subtype of pancreatic carcinoma. The aims of the study are to characterize the clinicopathological features and to evaluate the overall survival (OS) of patients with CC. Methods Patients diagnos…

Role of local therapy in the management of patients with metastatic anal squamous cell carcinoma: a National Cancer Database study Open

Rami P. Atallah, Yining Zhang, Katerina Zakka, Renjian Jiang, Zhonglu Huang , et al. · 2022

In addition to systemic therapy, resection of the primary tumor or palliative radiation improved OS in patients with anal SCCa. Patients unlikely to benefit from local control were those >70 years of age, male, lack of health insurance and…

Sex-related disparities in outcomes of cholangiocarcinoma patients in treatment trials Open

Matthew Ledenko, Samuel O. Antwi, Shiho Arima, Julia Driscoll, Junji Furuse , et al. · 2022

Background & aims. Cholangiocarcinoma (CCA) has historically been treated without regard to patient's biological sex. Although males and females differ considerably in physiology and drug metabolism, the effect of patient sex on treatment …

A randomized phase 2 trial of nivolumab, gemcitabine, and cisplatin or nivolumab and ipilimumab in previously untreated advanced biliary cancer: <span>BilT</span>‐01 Open

Vaibhav Sahai, Kent A. Griffith, Muhammad S. Beg, Walid L. Shaib, Devalingam Mahalingam , et al. · 2022

Background Gemcitabine and cisplatin has limited benefit as treatment for advanced biliary tract cancer (BTC). The addition of an anti‐programmed death receptor (PD‐1)/PD‐ligand (L1) antibody to either systemic chemotherapy or anti‐cytotox…

Survival Outcomes of Adjuvant Chemotherapy in Elderly Patients with Stage III Colon Cancer Open

Lana Khalil, Xingyu Gao, Jeffrey M. Switchenko, Olatunji B. Alese, Mehmet Akce , et al. · 2022

Background The survival impact of multi-agent (MAC) compared with single-agent (SAC) adjuvant chemotherapy (AC) in elderly patients with stage III colon cancer (CC) remains controversial. The aim of this study was to compare survival outco…

Comparing Somatostatin Analogs in the Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors Open

Mohammed Allaw, Jeffrey M. Switchenko, Lana Khalil, Christina Wu, Olatunji B. Alese , et al. · 2022

Background: The 2 approved somatostatin analogs (SSAs) in the first-line treatment of advanced, well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are octreotide long-acting release (Sandostatin LAR) …

Predictive and Prognostic Effects of Primary Tumor Size on Colorectal Cancer Survival Open

Olatunji B. Alese, Wei Zhou, Renjian Jiang, Katerina Zakka, Zhonglu Huang , et al. · 2021

Background Pathologic staging is crucial in colorectal cancer (CRC). Unlike the majority of solid tumors, the current staging model does not use tumor size as a criterion. We evaluated the predictive and prognostic impact of primary tumor …

High-Risk Features Are Prognostic in dMMR/MSI-H Stage II Colon Cancer Open

Amr Mohamed, Renjian Jiang, Philip A. Philip, Maria Diab, Madhusmita Behera , et al. · 2021

Background High-risk features, such as T4 disease, bowel obstruction, poorly/undifferentiated histology, lymphovascular, perineural invasion, and <12 lymph nodes sampled, indicate poor prognosis and define high-risk stage II disease in …

A multi-center, single-arm, phase Ib study of pembrolizumab (MK-3475) in combination with chemotherapy for patients with advanced colorectal cancer: HCRN GI14-186 Open

Cameron J. Herting, Matthew R. Farren, Yan Tong, Ziyue Liu, Bert H. O’Neil , et al. · 2021

Evaluating the impact of the Patient Preference Assessment Tool on clinicians' recommendations for phase I oncology clinical trials Open

Rachel Hianik, Taofeek K. Owonikoko, Jeffrey M. Switchenko, Margie D. Dixon, Walid L. Shaib , et al. · 2021

Objective Many groups recommend assessment of patient preferences particularly for patients with advanced, incurable cancer. We, therefore, developed the Patient Preference Assessment Tool (PPAT) to ascertain patient preferences in order t…

Multicenter, Open-Label, Phase I Study of DSP-7888 Dosing Emulsion in Patients with Advanced Malignancies Open

Alexander I. Spira, Aaron R. Hansen, Wael A. Harb, Kelly K. Curtis, Erina Koga‐Yamakawa , et al. · 2021

ClinicalTrials.gov identifier: NCT02498665.

Impact of Tumor Side on Clinical Outcomes in Stage II and III Colon Cancer With Known Microsatellite Instability Status Open

Mehmet Akce, Katerina Zakka, Renjian Jiang, S. Gill Williamson, Olatunji B. Alese , et al. · 2021

Background Tumor sidedness as a prognostic factor in advanced stage colon cancer (CC) is well established. The impact of tumor sidedness on the clinical outcomes of stage II and III CC has not been well studied. Methods The National Cancer…

Impact of high-risk features for stage II adenocarcinoma of the appendix Open

Mehmet Akce, Katerina Zakka, McKenna J. Penley, Renjian Jiang, Lana Khalil , et al. · 2021

High-risk stage II AA patients had significantly worse 5-year OS compared to low-risk patients. AC did not improve survival regardless of high-risk features in stage II AA in this retrospective study. A prospective randomized clinical tria…

330 Investigating the clinical safety, efficacy, and immune modulation of combined XL888 and pembrolizumab in metastatic gastrointestinal malignancies Open

Cameron J. Herting, Yuchen Zhang, Deon B. Doxie, Matthew R. Farren, Michael B. Ware , et al. · 2020

Background Both pancreatic ductal adenocarcinoma (PDAC) and metastatic colorectal cancer (mCRC) have yet to widely benefit from T cell-targeted immunotherapy and have universally poor prognoses. Thus, enhancing the activity of immunotherap…

In Reply Open

Walid L. Shaib · 2020

This letter to the editor responds to questions about the role of blood-based next-generation testing for appendiceal cancer, supporting its complementary role with tissue-based testing.

Phase 1 safety and pharmacodynamic study of lenalidomide combined with everolimus in patients with advanced solid malignancies with efficacy signal in adenoid cystic carcinoma Open

R. Donald Harvey, Bradley Curtis Carthon, Colleen Lewis, MM Hossain, Chao Zhang , et al. · 2020

Background Purpose: The combination of a mammalian target of rapamycin inhibitor and lenalidomide showed enhanced preclinical cytotoxicity. We conducted a phase 1 study in advanced solid tumour patients to assess safety, efficacy and pharm…

Survival outcome of adjuvant chemotherapy in deficient mismatch repair stage III colon cancer Open

Walid L. Shaib, K Zakka, Renjian Jiang, Ming Yan, Olatunji B. Alese , et al. · 2020

Background The prognostic impact of DNA mismatch repair (MMR) status remains controversial in patients with stage III colon cancer who are treated with adjuvant chemotherapy (AC). The aim of this study was to evaluate the survival outcome …

Radiation as a Single-Modality Treatment in Localized Pancreatic Cancer Open

Walid L. Shaib, Katerina Zakka, Asser A. Shahin, Fares Yared, Jeffrey M. Switchenko , et al. · 2020

Objectives Locally advanced pancreatic cancer (LAPC) is managed with multimodality therapy. We aim to evaluate the outcome of single-modality radiation therapy for LAPC. Methods Locally advanced pancreatic cancer patients were identified b…

Impact of High-Risk Features for Stage II Adenocarcinoma of the Appendix Open

Mehmet Akce, Katerina Zakka, McKenna J. Penley, Renjian Jiang, Olatunji B. Alese , et al. · 2020

Background: Clinico-pathological high-risk features are frequently utilized in adjuvant chemotherapy (AC) decisions in stage II colorectal cancer and their utility in stage II appendiceal adenocarcinoma (AA) is not established. The aim of …

Provider Recommendations for Phase I Clinical Trials Within a Shared Decision-Making Model in Phase I Cancer Clinical Trial Discussions Open

Rachel Hianik, Gavin P. Campbell, Eli Rowe Abernethy, Colleen Lewis, Christina Wu , et al. · 2020

PURPOSE: Debate continues over whether explicit recommendations for a clinical trial should be included as an element of shared decision making within oncology. We aimed to determine if and how providers make explicit recommendations in th…

Blood-based next-generation sequencing analysis of neuroendocrine neoplasms Open

Katerina Zakka, Rebecca J. Nagy, Leylah Drusbosky, Mehmet Akce, Christina Wu , et al. · 2020

Background: Neuroendocrine neoplasms (NENs) are a heterogeneous group of neoplasms that span from well-differentiated neuroendocrine tumors (NETs) to highly aggressive neoplasms classified as neuroendocrine carcinomas (NECs). The ge…

High-Grade Gastrointestinal Neuroendocrine Carcinoma Management and Outcomes: A National Cancer Database Study Open

Olatunji B. Alese, Renjian Jiang, Walid L. Shaib, Christina Wu, Mehmet Akce , et al. · 2020

The Oncologist 2019;24:911–920; first published on November 27, 2018; doi: 10.1634/theoncologist.2018-0382 The authors regret that the Acknowledgments section was omitted in the original publication of this article. The proper acknowledgme…

Immunologic alterations in the pancreatic cancer microenvironment of patients treated with neoadjuvant chemotherapy and radiotherapy Open

Matthew R. Farren, Layal Sayegh, Michael B. Ware, Hsiao-Rong Chen, Jingjing Gong , et al. · 2019

Pancreatic ductal adenocarcinoma (PDAC) has dismal 5-year survival (<9%). We hypothesize that exposure of tumors to conventional therapies may preferentially modulate immune biomarkers in the tumor microenvironment in PDAC. PDAC patients w…

Combined Effect of Sarcopenia and Systemic Inflammation on Survival in Patients with Advanced Stage Cancer Treated with Immunotherapy Open

Mehmet Asım Bilen, Dylan J. Martini, Yuan Liu, Julie M. Shabto, Jacqueline T. Brown , et al. · 2019

Background Sarcopenia and inflammation have been associated with poor survival in patients with cancer. We explored the combined effects of these variables on survival in patients with cancer treated with immunotherapy. Methods We performe…

Blood-Based Next-Generation Sequencing Analysis of Appendiceal Cancers Open

Walid L. Shaib, Katerina Zakka, Charles A. Staley, Ali Roberts, Mehmet Akce , et al. · 2019

Background Appendiceal cancers (ACs) are rare. The genomic landscape of ACs has not been well studied. The aim of this study was to confirm the feasibility of next-generation sequencing (NGS) using circulating tumor DNA (ctDNA) in ACs and …

Adiposity may predict survival in patients with advanced stage cancer treated with immunotherapy in phase 1 clinical trials Open

Dylan J. Martini, Meredith R. Kline, Yuan Liu, Julie M. Shabto, Milton Williams , et al. · 2019

Background Body mass index (BMI) is used to define obesity, but it is an imperfect measure of body composition. In the current study, the authors explored the association between types of fat and survival in patients treated with immunothe…

Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms Open

İbrahim Halil Şahin, Mehmet Akce, Olatunji B. Alese, Walid L. Shaib, Gregory B. Lesinski , et al. · 2019

Metastatic colorectal cancer (CRC) with a mismatch repair-deficiency (MMR-D)/microsatellite instability-high (MSI-H) phenotype carries unique characteristics such as increased tumour mutational burden and tumour-infiltrating lymphocytes. S…

Walid L. Shaib YOU? Author Swipe